Sepragen (SPGNA) and Neugenesis Corporation Collaborate on High Throughput Production of Antibodies in Fungal Expression System
4/17/2008 9:12:29 AM
HAYWARD, Calif.--(BUSINESS WIRE)--Sepragen Corporation (OTCBB:SPGNA), and Neugenesis Corporation jointly announced their collaboration to develop a means of high throughput, low cost production of monoclonal antibodies and vaccines for pandemic flu. The collaboration would involve Neugenesis growing its proprietary Neurospora expression system in Sepragen’s proprietary solid phase bioreactor system.
comments powered by